BR9810570A - Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina - Google Patents

Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina

Info

Publication number
BR9810570A
BR9810570A BR9810570-1A BR9810570A BR9810570A BR 9810570 A BR9810570 A BR 9810570A BR 9810570 A BR9810570 A BR 9810570A BR 9810570 A BR9810570 A BR 9810570A
Authority
BR
Brazil
Prior art keywords
inhibitor
aldose reductase
pharmaceutical composition
converting enzyme
angiotensin converting
Prior art date
Application number
BR9810570-1A
Other languages
English (en)
Inventor
Frank Carey
David Patrick Tuffin
Norman Eugene Cameron
Mary Anne Cotter
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9810570A publication Critical patent/BR9810570A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, E, USO DE INIBIDOR DE ALDOSE REDUTASE E UM INIBIDOR DE ENZIMA DE CONVERSãO DE ANGIOTENSINA" A invenção refere-se a composições farmacêuticas contendo um inibidor de aldose redutase e um inibidor de ACE, e seus usos no tratamento de complicações diabéticas tais como neuropatia diabética, retinopatia diabética e nefropatia diabética.
BR9810570-1A 1997-07-08 1998-07-02 Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina BR9810570A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714274.9A GB9714274D0 (en) 1997-07-08 1997-07-08 Pharmaceutical composition
PCT/GB1998/001959 WO1999002189A1 (en) 1997-07-08 1998-07-02 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor

Publications (1)

Publication Number Publication Date
BR9810570A true BR9810570A (pt) 2000-09-19

Family

ID=10815469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810570-1A BR9810570A (pt) 1997-07-08 1998-07-02 Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina

Country Status (28)

Country Link
US (1) US6337327B1 (pt)
EP (1) EP0991424B1 (pt)
JP (1) JP2002509540A (pt)
KR (1) KR20010015551A (pt)
CN (1) CN1186097C (pt)
AT (1) ATE205402T1 (pt)
AU (1) AU746211B2 (pt)
BR (1) BR9810570A (pt)
CA (1) CA2292451A1 (pt)
CZ (1) CZ290276B6 (pt)
DE (1) DE69801661T2 (pt)
DK (1) DK0991424T3 (pt)
ES (1) ES2163283T3 (pt)
GB (1) GB9714274D0 (pt)
HK (1) HK1028876A1 (pt)
HU (1) HU224009B1 (pt)
ID (1) ID24597A (pt)
IL (1) IL133004A (pt)
NO (1) NO20000045L (pt)
NZ (1) NZ501165A (pt)
PL (1) PL337925A1 (pt)
PT (1) PT991424E (pt)
RU (1) RU2216354C2 (pt)
SK (1) SK122000A3 (pt)
TR (1) TR199903026T2 (pt)
UA (1) UA64761C2 (pt)
WO (1) WO1999002189A1 (pt)
ZA (1) ZA985993B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) * 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6426341B1 (en) * 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
AU2002352145A1 (en) * 2001-11-26 2003-06-10 Bayer Healthcare Ag Regulation of human aldose reductase-like protein
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
KR102051030B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
WO2014022291A1 (en) * 2012-07-28 2014-02-06 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN103063794B (zh) * 2012-12-24 2014-08-06 扬子江药业集团南京海陵药业有限公司 一种依帕司他片的含量检测控制方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016978D0 (en) 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications

Also Published As

Publication number Publication date
US6337327B1 (en) 2002-01-08
HUP0002644A2 (hu) 2000-12-28
PT991424E (pt) 2002-02-28
SK122000A3 (en) 2000-06-12
UA64761C2 (uk) 2004-03-15
CZ290276B6 (cs) 2002-06-12
CZ200017A3 (cs) 2000-05-17
HK1028876A1 (en) 2001-03-09
DE69801661D1 (de) 2001-10-18
ES2163283T3 (es) 2002-01-16
CN1186097C (zh) 2005-01-26
PL337925A1 (en) 2000-09-11
AU8229698A (en) 1999-02-08
CA2292451A1 (en) 1999-01-21
KR20010015551A (ko) 2001-02-26
DE69801661T2 (de) 2002-07-04
NZ501165A (en) 2001-06-29
DK0991424T3 (da) 2001-12-03
AU746211B2 (en) 2002-04-18
ID24597A (id) 2000-07-27
IL133004A0 (en) 2001-03-19
CN1261804A (zh) 2000-08-02
ZA985993B (en) 1999-01-18
RU2216354C2 (ru) 2003-11-20
TR199903026T2 (xx) 2000-04-21
JP2002509540A (ja) 2002-03-26
GB9714274D0 (en) 1997-09-10
EP0991424A1 (en) 2000-04-12
WO1999002189A1 (en) 1999-01-21
NO20000045D0 (no) 2000-01-06
NO20000045L (no) 2000-01-06
HU224009B1 (hu) 2005-04-28
ATE205402T1 (de) 2001-09-15
IL133004A (en) 2004-12-15
EP0991424B1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
BR9810570A (pt) Composição farmacêutica, e, uso de inibidor de aldose redutase e um inibidor de enzima de conversão de angiotensina
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE69501591T2 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
WO2000059497A8 (en) Pyrrolidine modulators of chemokine receptor activity
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ES2124793T3 (es) Derivados de rapamicina alquilados en o y su uso, particularmente como inmunosupresores.
DE69842027D1 (de) Mutanten der alpha-amylase
BR0010220A (pt) Compostos de pirimidinona
AU2845599A (en) Pharmaceutical compositions and their use
BR9801652A (pt) Resorcinil-triazinas
AU3227700A (en) Skin sanitizing compositions
AU2525301A (en) Genus leontopodium plant extract and compositions containing same
LT2000087A (lt) Dezinfekavimo kompozicija
BR9408023A (pt) Formulações de fenbendazol
DE60116106D1 (de) Benzofuran derivate und ihre verwendung als antibakterielle wirkstoffe
ES2132383T3 (es) Inhibidores de proteasa hiv.
BR0307696A (pt) Composição desodorante ou antitranspirante
IL134930A0 (en) Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
ATE344242T1 (de) N-cyclopentylmodulatoren der chemokine rezeptoraktivität
AU7655600A (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
TR199800705T2 (pt)
ES2182340T3 (es) Oligonucleotidos quimericos y su uso.
DE69901104D1 (de) Verwendung von mikroorganismen extrakten in kosmetischen oder pharmazeutischen zusammensetzungen
HRPK970026B1 (en) Olive resorbent

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ALTERADO DE: ZENECA LIMITED

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: SYNGENTA LIMITED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.